Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

91 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-06

Study Completion Date

2027-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last for about 2 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity

NCT03308721

Metabolism and Nutrition Disorder Obesity

COMPLETED PHASE1

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

NCT04010786

Overweight Obesity

COMPLETED PHASE1

A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients

NCT00239174

Obesity

COMPLETED PHASE2

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

NCT01044108

Metabolism and Nutrition Disorder Obesity

TERMINATED PHASE1

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

NCT03661879

Metabolism and Nutrition Disorder Obesity

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants from the study INV-CL-108

Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.

Group Type EXPERIMENTAL

INV-347

Intervention Type DRUG

Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INV-347

Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
2. Male or female (sex at birth).
3. Age 18 years or above at the time of signing the informed consent.
4. Previously dosed with INV-347 in study INV-CL-108 and with measurable INV-347 concentration in plasma at enrolment \[above lower limit of qualification (LLOQ) of 0.5 nanogram per milliliter (ng/mL)\].

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes